Compare iShares MSCI Hong Kong ETF (EWH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06 (market cap $1.16B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: iShares MSCI Hong Kong ETF is the larger of the two by market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Sana Biotechnology Inc for 23 Days on average.
| EWH | SANA | |
|---|---|---|
Market Cap | $1.16B | $836.71M |
Volume | 3,176,523 | 4,507,444 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $5.92 |
52-Week Low | $20.66 | $2.68 |
Typical Hold Time | 61 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.06 with a 2.22% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though RSI levels suggest potential oversold conditions. Recent institutional activity includes Empowered Funds reducing its position by 70.2% in August 2026.
The outlook remains cautious given Hong Kong market volatility and geopolitical risks. Investment opportunity exists for contrarian investors if technical oversold conditions lead to rebound, but risks include continued Hang Seng weakness and macroeconomic pressures. Wall Street sentiment appears mixed with some seeing value while others reduce exposure.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
